Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analyzing the impact of ionizable lipid identity, purity, and stability on lipid nanoparticle performance.

Journal of pharmaceutical and biomedical analysis·2026
Same author

In honor of Prof. Véronique Préat.

Drug delivery and translational research·2026
Same author

Nanoemulsion-based colistin for pulmonary delivery: Enhanced antibacterial efficacy against Acinetobacter baumannii.

Drug delivery and translational research·2026
Same author

The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.

Drug delivery and translational research·2026
Same author

Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems.

Drug delivery and translational research·2026
Same author

Nanoassemblies for oral protein delivery - The case of monoclonals for inflammatory bowel disease.

Journal of controlled release : official journal of the Controlled Release Society·2025

Related Experiment Video

Updated: Jul 15, 2026

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system.

Alexander H Krauland1, María José Alonso

  • 1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Spain.

International Journal of Pharmaceutics
|April 27, 2007
PubMed
Summary

New chitosan (CS) and carboxymethyl-beta-cyclodextrin (CM-beta-CD) nanoparticles effectively carry macromolecular drugs like insulin and heparin. These nanoparticles offer tunable release profiles, enabling fast or slow delivery for various therapeutic applications.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

Related Experiment Videos

Last Updated: Jul 15, 2026

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery

Background:

  • Chitosan (CS) and carboxymethyl-beta-cyclodextrin (CM-beta-CD) are biocompatible polymers with potential in drug delivery.
  • Developing effective nanocarriers for macromolecular drugs remains a significant challenge in pharmaceutical research.

Purpose of the Study:

  • To synthesize novel nanoparticles combining CS and CM-beta-CD.
  • To evaluate the capacity of these nanoparticles for associating and delivering macromolecular drugs.
  • To characterize the physicochemical properties and drug release kinetics of the developed nanocarriers.

Main Methods:

  • Nanoparticles were prepared using the ionotropic gelation technique with CS, CM-beta-CD, and tripolyphosphate (TPP).
  • Physicochemical characterization included size, zeta potential, stability studies in simulated intestinal fluid, and elemental analysis.
  • Association efficiency and in vitro release profiles of insulin and heparin were determined.

Main Results:

  • Synthesized nanoparticles ranged from 231-383 nm with positive zeta potentials (+20.6 to +39.7 mV).
  • Nanoparticles demonstrated good stability in simulated intestinal fluid (pH 6.8) for at least 4 hours.
  • High association efficiencies were achieved for insulin (85.5-93.3%) and heparin (69.3-70.6%).
  • Insulin was rapidly released (84-97% in 15 min), while heparin showed sustained release (8.3-9.1% in 8h).

Conclusions:

  • CS-CM-beta-CD nanoparticles are promising nanocarriers for macromolecular drugs.
  • The developed nanocarriers exhibit tunable release characteristics, suitable for both fast and slow drug delivery.
  • These findings support the potential of CS-CD nanoparticles in advanced therapeutic strategies.